Feed Preview

Tau Antibody Therapy in Neurodegenerative Diseases

Tau Antibody Therapy in Neurodegenerative Diseases diagram by Kateryna Kon, Shutterstock
Kateryna Kon, Shutterstock

Tau vaccination and administration of anti-tau antibodies can prevent pathology and cognitive impairment in transgenic mouse models of tauopathy, suggesting that therapies which increase anti-tau antibodies might slow the development and/or progression of tauopathies including Alzheimer's disease. Here is the latest research.

Top 20 most recent papers
December 13, 2019
Review

Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways

Nature Reviews. Neurology
Steven M GreenbergSusanne J van Veluw
February 28, 2020

Generation and Characterization of Novel Monoclonal Antibodies Targeting p62/sequestosome-1 Across Human Neurodegenerative Diseases

Journal of Neuropathology and Experimental Neurology
Jorge A Trejo-LopezBenoit I Giasson
January 25, 2020
Review

Immunotherapy for Parkinson's disease

Neurobiology of Disease
Aaron D SchwabR Lee Mosley
March 3, 2020

Alzheimer's disease: phenotypic approaches using disease models and the targeting of tau protein

Expert Opinion on Therapeutic Targets
Elisabetta Lauretti, Domenico Praticò
February 13, 2020

Small molecule targeting of SHIP1 and SHIP2

Biochemical Society Transactions
William G KerrJohn D Chisholm
April 30, 2020
Open Access

Immunotherapies for Aging-Related Neurodegenerative Diseases-Emerging Perspectives and New Targets

Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics
Somin KwonEliezer Masliah
December 10, 2019

Active Immunotherapy to Prevent Alzheimer Disease-A DNA Amyloid β 1-42 Trimer Vaccine

JAMA Neurology
Roger N Rosenberg, Doris Lambracht-Washington
March 24, 2020
Review

Development of disease-modifying drugs for frontotemporal dementia spectrum disorders

Nature Reviews. Neurology
Francesco PanzaBruno P Imbimbo
December 10, 2019

Emerging roles of N- and C-terminally truncated Aβ species in Alzheimer's disease

Expert Opinion on Therapeutic Targets
Oliver Wirths, Silvia Zampar
April 17, 2020
Open Access

A Novel Tau Antibody Detecting the First Amino-Terminal Insert Reveals Conformational Differences Among Tau Isoforms

Frontiers in Molecular Biosciences
Joke VerelstDebby Thomas

See more papers from this feed

Related Feeds

ALS

Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease, is associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

ALS & FTD: TDP-43

ALS shares with a considerable proportion of FTD cases the same neuropathological substrate, namely, inclusions of abnormally phosphorylated protein tdp-43 (ptdp-43). Here are the latest discoveries pertaining to ptdp-43 and these diseases.

ALS - Pathogenic Mechanisms

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

ALS - Phenotypes

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating phenotypes associated with this genetically heterogeneous disorder.

ALS: Genetics

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Prions

Prions are misfolded proteins which characterize several fatal neurodegenerative diseases. Prion-like mechanisms are associated with the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Here are the latest discoveries pertaining to this disease.

ALS: Stress Granules

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by cytoplasmic protein aggregates within motor neurons. TDP-43 is an ALS-linked protein that is known to regulate splicing and storage of specific mRNAs into stress granules, which have been implicated in formation of ALS protein aggregates. Here is the latest research.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease, is associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS therapies here.

ALS: Transposon de-silencing

Transposon silencing is a form of transcriptional gene silencing. These gene silencing mechanisms are impaired in Amyotrophic lateral sclerosis (ALS). Here are the latest discoveries pertaining to transposon silencing and this disease.

Age-related Dementia

Age-related dementia (Alzheimer's disease) results from the destructive impact of the pulse on cerebral vasculature. Evidence is reviewed that the neuropathology of the dementia is caused by the breakdown of small cerebral vessels (silent microbleeds), that the microbleeds result from pulse-induced damage to the cerebral vessels, and that pulse becomes increasingly destructive with age, because of the age-related stiffening of the aorta and great arteries, which causes an increase in the intensity of the pressure pulse. Discover the latest research on age-related dementia here.

© 2020 Meta ULC. All rights reserved
/feed-previews/tau-antibody-therapy-in-neurodegenerative/d55e613b-55f6-4469-92e8-bd3a5ea2c43f